Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web


  Free Subscription


1 Eur J Gastroenterol Hepatol
1 Gastroenterol Hepatol
1 Gastroenterology
3 Hepatology
1 J Clin Gastroenterol
3 J Hepatol
3 J Med Virol
1 J Virol
1 Lancet
5 PLoS One
1 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Eur J Gastroenterol Hepatol

  1. KOUKOULIOTI E, Brodzinski A, Mihm U, Sarrazin C, et al
    Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections.
    Eur J Gastroenterol Hepatol. 2019 Feb 15. doi: 10.1097/MEG.0000000000001351.
    PubMed     Text format     Abstract available

    Gastroenterol Hepatol

  2. YU K, Du Z, Li Q, Cheng Q, et al
    Comparison of non-invasive models for predicting liver damage in chronic hepatitis B patients.
    Gastroenterol Hepatol. 2019 Feb 13. pii: S0210-5705(19)30025.
    PubMed     Text format     Abstract available


    Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor.
    Gastroenterology. 2019 Feb 15. pii: S0016-5085(19)30382.
    PubMed     Text format    


  4. BACKUS LI, Belperio PS, Shahoumian TA, Mole LA, et al
    Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Hepatology. 2018;68:827-838.
    PubMed     Text format     Abstract available

  5. JANIK MK, Wunsch E, Raszeja-Wyszomirska J, Krawczyk M, et al
    Depression: An Overlooked Villain in Autoimmune Hepatitis?
    Hepatology. 2019 Feb 17. doi: 10.1002/hep.30568.
    PubMed     Text format     Abstract available

  6. REN L, Zeng M, Tang Z, Li M, et al
    The anti-resection activity of the X protein encoded by Hepatitis Virus B.
    Hepatology. 2019 Feb 21. doi: 10.1002/hep.30571.
    PubMed     Text format     Abstract available

    J Clin Gastroenterol

  7. BISCHOFF J, Boesecke C, Ingiliz P, Berger F, et al
    Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
    J Clin Gastroenterol. 2019 Feb 15. doi: 10.1097/MCG.0000000000001189.
    PubMed     Text format     Abstract available

    J Hepatol

  8. PARK ES, Lee AR, Kim DH, Lee JH, et al
    Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30120.
    PubMed     Text format     Abstract available

  9. VERGIS N, Atkinson SR, Thursz MR
    The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
    J Hepatol. 2019 Feb 18. pii: S0168-8278(19)30030.
    PubMed     Text format    

  10. SINGH SP, Panigrahi S, Mishra D, Khatua CR, et al
    Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia.
    J Hepatol. 2019 Feb 16. pii: S0168-8278(19)30012.
    PubMed     Text format    

    J Med Virol

  11. WEI MT, Le AK, Chang MS, Hsu H, et al
    Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
    J Med Virol. 2019 Feb 18. doi: 10.1002/jmv.25433.
    PubMed     Text format     Abstract available

  12. WANG W, Zhao X, Li G, Wang L, et al
    Diagnostic Thresholds and Performance of Non-invasive Fibrosis Scores are Limited by Age in Patients with Chronic Hepatitis B.
    J Med Virol. 2019 Feb 20. doi: 10.1002/jmv.25435.
    PubMed     Text format     Abstract available

  13. BOGLIONE L, Lupia T, Cariti G, Ghisetti V, et al
    Antiviral treatment with PEG-IFN and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: a retrospective analysis.
    J Med Virol. 2019 Feb 22. doi: 10.1002/jmv.25438.
    PubMed     Text format     Abstract available

    J Virol

  14. FLECKEN T, Meier MA, Skewes-Cox P, Barkan DT, et al
    Mapping the heterogeneity of histone modifications on hepatitis B virus-DNA using liver needle biopsies obtained from chronically infected patients.
    J Virol. 2019 Feb 20. pii: JVI.02036-18. doi: 10.1128/JVI.02036.
    PubMed     Text format     Abstract available


  15. WILLIAMS R, Alexander G, Aspinall R, Batterham R, et al
    Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK.
    Lancet. 2018;392:2398-2412.
    PubMed     Text format     Abstract available

    PLoS One

  16. REUSCHEL E, Jilg W, Seelbach-Goebel B, Deml L, et al
    Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.
    PLoS One. 2019;14:e0212800.
    PubMed     Text format     Abstract available

  17. SKOGLUND C, Lagging M, Castedal M
    No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    PLoS One. 2019;14:e0211437.
    PubMed     Text format     Abstract available

  18. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0212033.
    PubMed     Text format     Abstract available

  19. TAKEUCHI F, Ikeda S, Tsukamoto Y, Iwasawa Y, et al
    Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor.
    PLoS One. 2019;14:e0212233.
    PubMed     Text format     Abstract available

  20. TUFON KA, Anong DN, Meriki HD, Georges TD, et al
    Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon.
    PLoS One. 2018;13:e0203312.
    PubMed     Text format     Abstract available


  21. KINGSTON NJ, Kurtovic L, Walsh R, Joe C, et al
    Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Vaccine. 2019 Feb 14. pii: S0264-410X(19)30132.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.